Gh Research PLC Schedule 13G passive stakes

RA Capital Management, along with its affiliates, has reported beneficial ownership of 7.1% of GH Research PLC's ordinary shares, totaling 4,897,182 shares.

Lynx1 Capital Management LP and Weston Nichols have disclosed a beneficial ownership of 13,263,288 ordinary shares, representing 19.3% of GH Research PLC.

Lynx1 Capital Management LP and Weston Nichols have disclosed a 17.4% beneficial ownership stake in GH Research PLC.

Lynx1 Capital Management LP and Weston Nichols have reported a 15.2% beneficial ownership stake in GH Research PLC.

Lynx1 Capital Management LP and Weston Nichols have increased their beneficial ownership in GH Research PLC to 16.8% of outstanding shares.

Theis Terwey has reported a 2.9% beneficial ownership stake in GH Research PLC, holding 1,784,266 ordinary shares.

Lynx1 Capital Management LP and Weston Nichols have reported a 13.9% beneficial ownership stake in GH Research PLC's Ordinary Shares.

RA Capital Management and its affiliates have reported a 12.4% beneficial ownership stake in GH Research PLC, totaling 7,676,697 ordinary shares.

Theis Terwey has disclosed a 7.6% beneficial ownership stake in GH Research PLC, holding 4,692,903 ordinary shares.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 8.2% in GH Research PLC's common stock as of June 30, 2025.

RA Capital Management, along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 11.2% in GH Research PLC as of March 31, 2025.

Multiple entities associated with Biotechnology Value Fund, including Mark N. Lampert, have collectively reported beneficial ownership of 14.2% of GH Research PLC's ordinary shares as of March 31, 2025.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have filed an amended Schedule 13G disclosing a shared beneficial ownership of 8.9% in GH Research PLC's ordinary shares.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a beneficial ownership of 6.9% of GH Research PLC's common stock as of March 31, 2025.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 4.8% in GH Research PLC's common stock as of December 31, 2024, indicating a reduction below the 5% threshold.

Lynx1 Capital Management LP and its sole member, Weston Nichols, have disclosed a significant 10.2% beneficial ownership stake in GH Research PLC.

Lynx1 Capital Management LP and Weston Nichols have jointly reported a beneficial ownership of 9.3% in GH Research PLC, totaling 4,858,994 ordinary shares as of December 31, 2024.